Drug Trial Radar · NCT03296527
Efficacy and Safety of FE 999049 in Controlled Ovarian Stimulation in Pan-Asian Women
Last checked: Nov 19, 2026Latest source record: Aug 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,011
Actual
Start
Dec 1, 2017
Primary completion
Jan 3, 2020
Study completion Jul 26, 2020
Sponsor
- Lead sponsor
- Ferring PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Sep 28, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 20 years, up to 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To demonstrate non-inferiority of FE 999049 compared with GONAL-F with respect to ongoing pregnancy rate in women undergoing controlled ovarian stimulation.
Conditions
- Controlled Ovarian Simulation
Interventions
Follitropin alfaDrug
GONAL-F dose was fixed for the first 5 stimulation days.
Follitropin deltaDrug
REKOVELLE (FE 999049) was fixed throughout the stimulation period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Ongoing Pregnancy RateTime frame: 10-11 weeks after transfer
Locations
26 sites in 4 countries. Site status is shown where the registry gives one.
Beijing Obstetrics and Gynecology Hospital,Capital Medical University
Beijing, China
Medical Center for Human Reproduction, Peking University Third Hospital
Beijing, China
Peking University First Hospital
Beijing, China
West China Second University Hospital of Sichuan University
Chengdu, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, China
The Sixth Affiliated Hospital of Sun Yat-sen University
Guangzhou, China
The Third Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
The First Affiliated Hospital of An'hui Medical University
Hefei, China
Jiangsu Province Hospital
Nanjing, China
ShengJing Hospital of China Medical University
Shenyang, China
Peking University Shenzhen Hospital
Shenzhen, China
Tianjin Central Hospital of Gynaecology and Obstetrics
Tianjin, China
Tianjin Medical University General Hospital
Tianjin, China
Renmin Hospital of Wuhan University
Wuhan, China
Tongji Hospital,Tongji Medical College, Huazhong University of Science & Technology
Wuhan, China
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China
Seoul National University Bundang Hospital
Seongnam-si, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Taichung Veterans General Hospital
Taichung, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Taipei Medical University Hospital
Taipei, Taiwan
Chang Gung Memorial Hospital
Taoyuan, Taiwan
National Center for Assisted Reproductive Technology
Hanoi, Vietnam
My Duc Hospital
Ho Chi Minh City, Vietnam
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.